Peptide Encyclopedia / P-21
EncyclopediaP-21 is a synthetic neurogenic peptide, an 11-mer with an adamantane-based unnatural amino acid, derived from a CNTF fragment and studied for neurogenesis and reduced tau in Alzheimer's models. The FDA has not approved it, it trades gray-market, and the data stay preclinical and rodent-only. Educational only, not medical advice.
| Category | Cognitive |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A synthetic neurogenic peptidergic compound (an 11-mer derivative incorporating an adamantane-based unnatural amino acid) derived from a fragment of CNTF. In preclinical work it is proposed to enhance neurogenesis, BDNF signaling, and synaptic plasticity, and to reduce tau pathology in Alzheimer's disease models. Developed by a US-based academic group (Iqbal lab), distinct from the Russian bioregulator class.
uncertain / limited human pharmacokinetic data; no validated human PK is available.
Not FDA-approved; research chemical / gray-market in the US. Not an approved drug in any jurisdiction. Not on FDA compounding lists.
No meaningful human safety data exist; characterization is essentially limited to rodent studies. Long-term effects, immunogenicity, and effects of chronic neurogenic stimulation in humans are unknown. Gray-market purity is unverified.
Preclinical only. Promising rodent data on cognition and Alzheimer's models from a small number of academic studies; no human clinical trials and no independent confirmation of human efficacy or safety.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. P-21 may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
